Medical - Diagnostics & Research
Compare Stocks
2 / 10Stock Comparison
PRPO vs NTRA
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Diagnostics & Research
PRPO vs NTRA — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Medical - Diagnostics & Research | Medical - Diagnostics & Research |
| Market Cap | $53M | $31.16B |
| Revenue (TTM) | $22M | $2.31B |
| Net Income (TTM) | $-1M | $-208M |
| Gross Margin | 47.5% | 64.8% |
| Operating Margin | -9.7% | -13.4% |
| Total Debt | $1M | $214M |
| Cash & Equiv. | $1M | $1.08B |
PRPO vs NTRA — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Precipio, Inc. (PRPO) | 100 | 181.4 | +81.4% |
| Natera, Inc. (NTRA) | 100 | 501.3 | +401.3% |
Price return only. Dividends and distributions are not included.
Quick Verdict: PRPO vs NTRA
Each card shows where this stock fits in a portfolio — not just who wins on paper.
PRPO carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- beta 0.41
- Lower volatility, beta 0.41, Low D/E 10.4%, current ratio 0.81x
- Beta 0.41, current ratio 0.81x
NTRA is the clearest fit if your priority is growth exposure and long-term compounding.
- Rev growth 35.9%, EPS growth 0.7%, 3Y rev CAGR 41.1%
- 20.9% 10Y total return vs PRPO's -98.9%
- 35.9% revenue growth vs PRPO's 5.1%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 35.9% revenue growth vs PRPO's 5.1% | |
| Value | Better valuation composite | |
| Quality / Margins | -5.8% margin vs NTRA's -9.0% | |
| Stability / Safety | Beta 0.41 vs NTRA's 1.26, lower leverage | |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | +367.7% vs NTRA's +37.3% | |
| Efficiency (ROA) | -5.9% ROA vs NTRA's -10.6%, ROIC -24.3% vs -36.1% |
PRPO vs NTRA — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
PRPO vs NTRA — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
NTRA leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
NTRA is the larger business by revenue, generating $2.3B annually — 107.1x PRPO's $22M. Profitability is closely matched — net margins range from -5.8% (PRPO) to -9.0% (NTRA). On growth, NTRA holds the edge at +39.8% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $22M | $2.3B |
| EBITDAEarnings before interest/tax | -$549,000 | -$310M |
| Net IncomeAfter-tax profit | -$1M | -$208M |
| Free Cash FlowCash after capex | $589,000 | $97M |
| Gross MarginGross profit ÷ Revenue | +47.5% | +64.8% |
| Operating MarginEBIT ÷ Revenue | -9.7% | -13.4% |
| Net MarginNet income ÷ Revenue | -5.8% | -9.0% |
| FCF MarginFCF ÷ Revenue | +2.7% | +4.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | +18.3% | +39.8% |
| EPS Growth (YoY)Latest quarter vs prior year | +88.1% | +185.4% |
Valuation Metrics
PRPO leads this category, winning 3 of 4 comparable metrics.
Valuation Metrics
| Metric | ||
|---|---|---|
| Market CapShares × price | $53M | $31.2B |
| Enterprise ValueMkt cap + debt − cash | $53M | $30.3B |
| Trailing P/EPrice ÷ TTM EPS | -10.38x | -144.62x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 3.32x | 13.51x |
| Price / BookPrice ÷ Book value/share | 3.68x | 17.55x |
| Price / FCFMarket cap ÷ FCF | 245.72x | 285.53x |
Profitability & Efficiency
PRPO leads this category, winning 6 of 8 comparable metrics.
Profitability & Efficiency
PRPO delivers a -9.1% return on equity — every $100 of shareholder capital generates $-9 in annual profit, vs $-15 for NTRA. PRPO carries lower financial leverage with a 0.10x debt-to-equity ratio, signaling a more conservative balance sheet compared to NTRA's 0.13x.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | -9.1% | -15.3% |
| ROA (TTM)Return on assets | -5.9% | -10.6% |
| ROICReturn on invested capital | -24.3% | -36.1% |
| ROCEReturn on capital employed | -30.5% | -18.3% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 5 |
| Debt / EquityFinancial leverage | 0.10x | 0.13x |
| Net DebtTotal debt minus cash | -$136,000 | -$862M |
| Cash & Equiv.Liquid assets | $1M | $1.1B |
| Total DebtShort + long-term debt | $1M | $214M |
| Interest CoverageEBIT ÷ Interest expense | -13.58x | -25.21x |
Total Returns (Dividends Reinvested)
NTRA leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in NTRA five years ago would be worth $21,587 today (with dividends reinvested), compared to $3,958 for PRPO. Over the past 12 months, PRPO leads with a +367.7% total return vs NTRA's +37.3%. The 3-year compound annual growth rate (CAGR) favors NTRA at 60.6% vs PRPO's 36.3% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | +27.6% | -3.9% |
| 1-Year ReturnPast 12 months | +367.7% | +37.3% |
| 3-Year ReturnCumulative with dividends | +153.3% | +314.0% |
| 5-Year ReturnCumulative with dividends | -60.4% | +115.9% |
| 10-Year ReturnCumulative with dividends | -98.9% | +2089.4% |
| CAGR (3Y)Annualised 3-year return | +36.3% | +60.6% |
Risk & Volatility
PRPO leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
PRPO is the less volatile stock with a 0.41 beta — it tends to amplify market swings less than NTRA's 1.26 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. PRPO currently trades 90.4% from its 52-week high vs NTRA's 85.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.41x | 1.26x |
| 52-Week HighHighest price in past year | $33.61 | $256.36 |
| 52-Week LowLowest price in past year | $5.94 | $131.81 |
| % of 52W HighCurrent price vs 52-week peak | +90.4% | +85.7% |
| RSI (14)Momentum oscillator 0–100 | 53.9 | 57.1 |
| Avg Volume (50D)Average daily shares traded | 30K | 1.3M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $262.50 |
| # AnalystsCovering analysts | — | 27 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
PRPO leads in 3 of 6 categories (Valuation Metrics, Profitability & Efficiency). NTRA leads in 2 (Income & Cash Flow, Total Returns).
PRPO vs NTRA: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is PRPO or NTRA a better buy right now?
For growth investors, Natera, Inc.
(NTRA) is the stronger pick with 35. 9% revenue growth year-over-year, versus 5. 1% for Precipio, Inc. (PRPO). Analysts rate Natera, Inc. (NTRA) a "Buy" — based on 27 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — PRPO or NTRA?
Over the past 5 years, Natera, Inc.
(NTRA) delivered a total return of +115. 9%, compared to -60. 4% for Precipio, Inc. (PRPO). Over 10 years, the gap is even starker: NTRA returned +20. 9% versus PRPO's -98. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — PRPO or NTRA?
By beta (market sensitivity over 5 years), Precipio, Inc.
(PRPO) is the lower-risk stock at 0. 41β versus Natera, Inc. 's 1. 26β — meaning NTRA is approximately 206% more volatile than PRPO relative to the S&P 500. On balance sheet safety, Precipio, Inc. (PRPO) carries a lower debt/equity ratio of 10% versus 13% for Natera, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — PRPO or NTRA?
By revenue growth (latest reported year), Natera, Inc.
(NTRA) is pulling ahead at 35. 9% versus 5. 1% for Precipio, Inc. (PRPO). On earnings-per-share growth, the picture is similar: Precipio, Inc. grew EPS 35. 0% year-over-year, compared to 0. 7% for Natera, Inc.. Over a 3-year CAGR, NTRA leads at 41. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — PRPO or NTRA?
Natera, Inc.
(NTRA) is the more profitable company, earning -9. 0% net margin versus -26. 9% for Precipio, Inc. — meaning it keeps -9. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NTRA leads at -13. 4% versus -26. 4% for PRPO. At the gross margin level — before operating expenses — NTRA leads at 64. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — PRPO or NTRA?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is PRPO or NTRA better for a retirement portfolio?
For long-horizon retirement investors, Precipio, Inc.
(PRPO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 41)). Both have compounded well over 10 years (PRPO: -98. 9%, NTRA: +20. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between PRPO and NTRA?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: PRPO is a small-cap quality compounder stock; NTRA is a mid-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.